Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial
about
Certolizumab pegol (CDP870) for rheumatoid arthritis in adultsAre patient-reported outcome instruments for ankylosing spondylitis fit for purpose for the axial spondyloarthritis patient? A qualitative and psychometric analysisComparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analyHealth-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT.Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds.Comparative efficacy of biological agents in methotrexate-refractory rheumatoid arthritis patients: a Bayesian mixed treatment comparison.Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials.The efficacy and safety of certolizumab pegol (CZP) in the treatment of active rheumatoid arthritis (RA): a meta-analysis from nine randomized controlled trials.Renal and Gastrointestinal Considerations in Joint Replacement Surgery.Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trialCellular and humoral mechanisms involved in the control of tuberculosisImprovements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE studyImpact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity.Determinants of Disability in Rheumatoid Arthritis: A Community-Based Cohort Study.Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritisSarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.Impact of Certolizumab Pegol on Patient-Reported Outcomes in Patients With Axial Spondyloarthritis.Certolizumab in the long-term treatment of rheumatoid arthritis.Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis.Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006.Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.Certolizumab pegol: a review of its use in the management of rheumatoid arthritis.Certolizumab pegol in rheumatoid arthritis: current update.Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice.Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis.Certolizumab Pegol: A Review in Inflammatory Autoimmune Diseases.Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-naïve patients with rheumatoid arthritis.Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial.Power and sample size determination for group comparison of patient-reported outcomes using polytomous Rasch models.Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.Efficacy and safety of methotrexate plus certolizumab pegol or placebo in active rheumatoid arthritis
P2860
Q24193535-2B5E8F49-B3C2-475E-9BC3-83F474E524A2Q26823664-0156AF53-2AFB-4841-A9FC-F7FD9166D3A3Q27694496-8595EE54-9186-4337-9022-2895D128E97FQ30957102-A36D61E0-8BCD-4CA4-94B2-ACD6B2916F75Q33591510-571411EC-1E6C-42F1-9177-877D15050817Q33690668-DFD09349-9387-426E-98BE-085F1FDE42B6Q34478853-8BD6A2B0-8034-4652-B50E-027A34EC5F67Q34769757-45C6F45D-4A9D-4A7F-B820-12CDFA8A9D41Q35207986-BEAA2077-4DEC-44BF-BFDA-5CFAD85C8903Q35351313-9AA715F7-86D4-434B-9730-CA2E634EE35DQ35996521-1555A78F-89BF-451F-BC55-A19B4092E063Q36252760-E2113907-13E6-4CCD-9D41-877689AC2984Q36327384-BC7E9627-3EC8-4CC4-8AAB-7D629264CACAQ36542897-BD59C450-D585-45D5-B717-4115688A94ACQ36910016-440B876D-24BD-4CE9-9B83-FB5C37B7C499Q37233468-FDE2636A-4DEF-47B4-9527-CCA76756AFF9Q37320545-1B2A6E7E-F16D-4047-BAD7-F9D9C1C51E12Q37358254-8D2A6B36-9485-4463-9E07-502DAB62918DQ37587412-9B16BACE-BBDF-4F03-BC76-9826F47D8D7EQ37595993-22E6369B-137C-42DF-B013-14779B1AB103Q37704288-57CE4654-024F-4136-9621-A3DAEA28779AQ38075801-98E1290F-3E0D-440F-9BBE-1B6471827020Q38198118-AC99DBFC-4C42-4CBC-B65C-68A1F19A3373Q38200927-BA9777AE-AB8E-450C-B4B5-7B64FC8DA5E3Q38939820-CC54AAE2-AB75-45AB-82BF-E5477E0E859AQ38972531-59A4B742-3FE3-476A-B1B5-B8FB62C33B9CQ39230189-CE3A2520-86C3-4EB3-9038-0068A67D989FQ41184418-CC266147-D729-4388-AD2B-7C1E6B5DA0DBQ44818742-26FAC42A-E45B-4C0B-B9BF-5027A27C1CA9Q47399326-6FF8B2BC-47F8-463C-9EF1-E26AB3AFB85CQ47836056-859016F7-E095-4558-8253-6B9F118BF0CCQ57330038-21776F91-93B7-46C8-993D-34125F3A7AE6
P2860
Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Certolizumab pegol plus methot ...... utcomes from the RAPID 2 trial
@ast
Certolizumab pegol plus methot ...... utcomes from the RAPID 2 trial
@en
Certolizumab pegol plus methot ...... utcomes from the RAPID 2 trial
@nl
type
label
Certolizumab pegol plus methot ...... utcomes from the RAPID 2 trial
@ast
Certolizumab pegol plus methot ...... utcomes from the RAPID 2 trial
@en
Certolizumab pegol plus methot ...... utcomes from the RAPID 2 trial
@nl
prefLabel
Certolizumab pegol plus methot ...... utcomes from the RAPID 2 trial
@ast
Certolizumab pegol plus methot ...... utcomes from the RAPID 2 trial
@en
Certolizumab pegol plus methot ...... utcomes from the RAPID 2 trial
@nl
P2093
P2860
P50
P356
P1476
Certolizumab pegol plus methot ...... utcomes from the RAPID 2 trial
@en
P2093
Dinesh Khanna
Enkeleida Nikaï
Falk Hiepe
Geoffroy Coteur
Michael Schiff
Philip Mease
Vibeke Strand
P2860
P304
P356
10.1136/ARD.2010.143586
P407
P577
2011-03-17T00:00:00Z